Anthera Pharmaceuticals Provides Business Update And Reports 2016 Third Quarter Financial Results

  • Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminent
  • Data and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura™
  • FDA Type C meeting in September validated basis for BLA filing and manufacturing approach for Sollpura™
  • Closing of initial $17 million registered direct offering
  • Appointed William Shanahan Jr., M.D., J.D. as Chief Medical Officer

HAYWARD, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the third quarter ended September 30, 2016.

Recent Developments and Business Highlights:

Blisibimod for the treatment of  Systemic Lupus Erythematosus ("SLE")
  • Topline Data from Phase 3 CHABLIS-SC1 Clinical Study We have been working diligently through the adjudication for the CHABLIS-SC-1 study, which completed the last patient visit in September.  We currently plan to report topline efficacy and safety data prior to the 2016 American College of Rheumatology Annual Meeting taking place from November 11 th to November 16 th.  Topline data from the CHABLIS-SC1 will include the primary endpoint evaluation, the Systemic Lupus Erythematosus Responder Index (SRI-6) as well as safety and tolerability data from the study. For more information on the CHABLIS-SC1 study, please visit http://www.anthera.com/clinical-studies/chablis_sc/.
  • Phase 3 CHABLIS 7.5 Clinical Study Enrollment and Clinical Site Activation On Track We continued further clinical site activation for, and enrollment in CHABLIS 7.5, our second Phase 3 clinical study. This study will evaluate the efficacy and safety of blisibimod in patients who, despite corticosteroid use, continue to have clinically-active lupus (SLE) and the presence of anti-double-stranded DNA and low complements which are known serological markers of lupus. For more information about the CHABLIS 7.5 study, visit http://www.anthera.com/clinical-studies/chablis_7-5/.  

If you liked this article you might like

Twitter, Coty, Micron Technology: Doug Kass' Views

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Make You a Lot of Money

Anthera Pharmaceuticals (ANTH) Is Weak On High Volume Today

3 Biotech Stocks Under $10 Making Big Moves